UNASSIGNED: In accordance with PRISMA guidelines, articles were systematically searched for in databases and clinical trial registries.
UNASSIGNED: A total of 4 preclinical trials and 3 randomized controlled trials (RCTs) were included in this review. A 4-week RCT observed a difference of 24.0 points (SD 21.0) in the Positive and Negative Syndrome Scale (PANSS) total score between xanomeline and placebo groups (p = 0.039). A 5-week RCT observed PANSS total score changes from baseline to week 5, including -17.4 and -5.9 points in KarXT and placebo groups, respectively (LSMD -11.6 points; 95% CI -16.1 to -7.1; p < 0.001; d = 0.75). Another 5-week RCT observed PANSS total score changes from baseline to week 5, including -21.2 (SE 1.7) and -11.6 (SE 1.6) points in KarXT and placebo groups, respectively (LSMD -9.6; 95% CI -13.9 to -5.2; p < 0.0001; d = 0.61). Side effects include constipation, nausea, vomiting, dyspepsia, and dry mouth.
UNASSIGNED: KarXT offers an innovative non-D2 blocking approach, representing a promising treatment avenue for schizophrenia.
■根据PRISMA指南,在数据库和临床试验登记处系统检索了文章.
■本综述共纳入4项临床前试验和3项随机对照试验(RCT)。4周的RCT观察到xanomeline组和安慰剂组之间的阳性和阴性综合征量表(PANSS)总分差异为24.0分(SD21.0)(p=0.039)。5周的RCT观察到PANSS总分从基线到第5周的变化,包括KarXT和安慰剂组的-17.4和-5.9分,分别(LSMD-11.6分;95%CI-16.1至-7.1;p<0.001;d=0.75)。另一个5周的RCT观察到PANSS总分从基线到第5周的变化,包括KarXT和安慰剂组的-21.2(SE1.7)和-11.6(SE1.6)分,分别(LSMD-9.6;95%CI-13.9至-5.2;p<0.0001;d=0.61)。副作用包括便秘,恶心,呕吐,消化不良,口干。
■KarXT提供了一种创新的非D2阻塞方法,代表精神分裂症有希望的治疗途径。